Apoptosis in gliomas, and its role in their current and future treatment

被引:39
作者
Bögler, O
Weller, M
机构
[1] Henry Ford Hosp, Dept Neurosurg, Hermelin Brain Tumor Ctr, Lab Brain Tumor Biol, Detroit, MI 48202 USA
[2] Univ Tubingen, Sch Med, Dept Neurol, Mol Neurooncol Lab, Tubingen, Germany
关键词
glioma; hypoxia; apoptosis; p21; Apo2L/TRAIL; CD95L; EGFR; BCL-2; BAX; review;
D O I
10.2741/bogler
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Apoptosis has recently entered the spotlight in the continuing search for new therapeutic approaches to cancer because it plays a twofold role in this disease. As stated by Lowe and Lin: "(M)ost cytotoxic anticancer agents induce apoptosis.( and so) the same mutations that suppress apoptosis during tumor development also reduce treatment sensitivity" (1). Therefore, any strategy aimed at increasing the propensity of glioma cells to undergo apoptosis could be therapeutic in its own right, but has the added potential of enhancing their sensitivity to other, established, treatments. As a corollary, understanding apoptotic mechanisms at the molecular level will not only help to explain why gliomas arise, but also identify points of intervention. This review will focus on these points, with emphasis on two families of apoptotic molecules, death ligands and their receptors, and BCL-2 family proteins. Near-term strategies of how apoptosis can be exploited therapeutically are discussed.
引用
收藏
页码:E339 / E353
页数:15
相关论文
共 125 条
[1]   The Bcl-2 protein family: Arbiters of cell survival [J].
Adams, JM ;
Cory, S .
SCIENCE, 1998, 281 (5381) :1322-1326
[2]  
Afra D, 2002, LANCET, V359, P1011
[3]   Treatment of experimental glioma by administration of adenoviral vectors expressing Fas ligand [J].
Ambar, BB ;
Frei, K ;
Malipiero, U ;
Morelli, AE ;
Castro, MG ;
Lowenstein, PR ;
Fontana, A .
HUMAN GENE THERAPY, 1999, 10 (10) :1641-1648
[4]  
[Anonymous], 2000, World Health Organisation Classification of Tumours: Pathology and genetics of tumours of the nervous system
[5]   Safety and antitumor activity of recombinant soluble Apo2 ligand [J].
Ashkenazi, A ;
Pai, RC ;
Fong, S ;
Leung, S ;
Lawrence, DA ;
Masters, SA ;
Blackie, C ;
Chang, L ;
McMurtrey, AE ;
Hebert, A ;
DeForge, L ;
Koumenis, IL ;
Lewis, D ;
Harris, L ;
Bussiere, J ;
Koeppen, H ;
Shahrokh, Z ;
Schwall, RH .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) :155-162
[6]   Death receptors: Signaling and modulation [J].
Ashkenazi, A ;
Dixit, VM .
SCIENCE, 1998, 281 (5381) :1305-1308
[7]   Fas expression on human fetal astrocytes without susceptibility to fas-mediated cytotoxicity [J].
Becher, B ;
D'Souza, SD ;
Troutt, AB ;
Antel, JP .
NEUROSCIENCE, 1998, 84 (02) :627-634
[8]  
Begemann M, 1998, ANTICANCER RES, V18, P3139
[9]   CONVECTION-ENHANCED DELIVERY OF MACROMOLECULES IN THE BRAIN [J].
BOBO, RH ;
LASKE, DW ;
AKBASAK, A ;
MORRISON, PF ;
DEDRICK, RL ;
OLDFIELD, EH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (06) :2076-2080
[10]  
Bögler O, 2000, NEURO-ONCOLOGY, V2, P6, DOI 10.1093/neuonc/2.1.6